Introduction {#sec1-1}
============

Cervical cancer is one of the most common cancers in women worldwide with more than 200000 deaths, annually ([@ref1]). Approximately 80% of them live in developing countries where this disease is detected at late stage; so, new treatment drugs for cervical cancer are needed ([@ref2], [@ref3]).

Development of cervical cancer is caused by high-risk human papillomaviruses (hrHPVs) ([@ref4]). They are small, nonenveloped, and nonlytic viruses with dsDNA genome that are tropic for squamous epidermis. The cervical carcinogenesis is associated with E6 and E7 oncoproteins from hrHPVs ([@ref4]). E6 and E7 viral oncogenic proteins inactivate two cellular tumor suppressor proteins p53 and pRB, respectively ([@ref5], [@ref6]), and are necessary for cells proliferation and DNA damage that eventually lead to cancer ([@ref7]).

The development of cervical cancer related to changes in epigenetic patterns of cells such as DNA methylation, histone methylation, and histone acetylation ([@ref8]). Histone acetylation is one of the most important epigenetic mechanisms that neutralizes the positive charge of histone proteins, unfolds the chromatin structure and associated DNA, and induces transcription and gene expression ([@ref9]).

The acetylation of histone proteins is regulated by histone acetyltransferase (HATs) and histone deacetylases (HDACs). HDACs remove the acetyl groups on the lysine residues of histones and induce positive charge on histone proteins, this leads to aberrant transcription and gene suppression. So, HDACs could reduce the expression of tumor suppressor genes to development of cancer ([@ref10]).

Histone deacetylase inhibitors (HDACIs) have appeared as the promising drugs for cancer ([@ref11], [@ref12]). HDACIs have been classified to 5 groups: 1. short chain fatty acids (e.g., butyrates and valproic acid), 2. organic hydroxamic acids (e.g., suberoylanilide bishydroxamine (SAHA) and trichostatin A (TSA), 3. sulfonamide anilides, 4. benzamides (e.g., MS-275), 5. cyclic tetrapeptides ([@ref13]).

Among HDACIs, valproic acid (VPA) has been demonstrated as a drug with anticancer properties. VPA is used for treatment of cluster migraine, headaches, and epilepsy ([@ref14]), but antineoplastic activity of VPA was shown in 1997 ([@ref15]). VPA increases apoptosis and reduces angiogenic activity in various tumor cells ([@ref16]). It also inhibits invasion and migration of tumor cells by several mechanisms ([@ref16]-[@ref19]).

To start the process of invasion and metastasis, a malignant cell must first break away from the cancerous tumor. In cancer cells, the expression of adhesion molecules seems to be reduced. E-cadherin is one of the most important adhesion molecules encoded by CDH~1~ gene, and the dominant epithelial cell-adhesion molecule. This protein is expressed on basal and suprabasal cells and plays important role in epithelial structural integrity ([@ref20], [@ref21]). The suppression of E-cadherin expression has been widely reported in different epithelial tumors ([@ref22]-[@ref27]). The loss of E-cadherin is associated with invasion and metastasis ([@ref28]).

In this work, we compare the effects of VPA on E-cadherin expression in two groups of cell lines, HPV positive and HPV negative cell lines. Also, we study the effects of VPA on E7 oncoprotein expression in HPV positive cell lines.

Materials and Methods {#sec1-2}
=====================

Cell culture {#sec2-1}
------------

The HPV positive cell line; HeLa, a cervical carcinoma cell line that contains HPV~18~ DNA, and TC~1~ which is transduced to express the E6 and E7 oncogenes of HPV~16~, were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco). Growth media was supplemented with 10% heat inactivated fetal calf serum (Life Technologies, Camarillo, CA, USA), 100 μg/ml penicillin/streptomycin (Invitrogen, Life Technologies, Camarillo, CA, USA), and 2 mM L-glutamine (Sigma-Aldrich, MO, USA). The HPV negative cell lines; HCT~116~ and MKN~45~, were also cultured in the same condition. All of the cell lines were maintained in humidified incubator with 5% CO~2~.

Valproic acid preparation {#sec2-2}
-------------------------

Valproate sodium salt was prepared from sigma (Sigma-Aldrich, MO, USA) and was dissolved in phosphate buffered saline (PBS) to 1, 2, and 5 mM concentrations.

Proliferation assay {#sec2-3}
-------------------

Cell proliferation was performed using the 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) dye reduction assay. HeLa, TC~1~, HCT~116~, and MKN~45~ cell lines were seeded at a density of 5×10^4^ per well in 96 well culture plates and incubated overnight with DMEM containing 10% fetal calf serum. After 24 hr, the cells were treated with medium containing VPA at concentrations of 0, 1, 2, and 5 mmol/L, for three days. After 24, 48, and 72 hr, MTT was added at concentration of 0/5 mg/ml for 4 hr. The absorbance was determined at 570 nm.

RNA preparation {#sec2-4}
---------------

The four cell lines (HCT~116~, MKN~45~, HeLa, and TC~1~) were cultured in 12 well culture plates to 80 percent confluency and were treated with medium containing 2 mmol/l VPA for 48 hr. According to experimental studies, our experiments were performed three times to achieve valid results; so, we did real-time PCR analysis for each experiment using 3 samples. The cells were harvested and resuspended in 250 μl volume of sterile PBS. Total RNA was extracted from cells using TriPure total RNA isolation Kit according to the manufacturer's procedure (Roche Applied science, Indianapolis, IN, USA). Extracted RNA concentration and purity were analyzed at the wavelength of 260 nm by nanodrop spectrophotometry (Eppendrof, Humburg, Germany). RNA integrity was visually assessed with 1% agarose gel electrophoresis. The RNA with absorption ratio OD 260 nm OD 280 nm between 1/8 and 2 was used for cDNA synthesis.

cDNA synthesis {#sec2-5}
--------------

cDNA was prepared from total RNA by reverse transcription using M-MuLV reverse transcriptase (Fermentas, Vilnius, Lithuania), random hexamers, and RNase inhibitor (Vivantis). One μg of RNA was added by 2 μl of 10 mM dNTPs along with 1 μl of (0.2 μg/μl) random hexamer, 1 μl (20 u/μl) of M-MuLV, and 0.5 μl of RNase inhibitor in a sterile microcentrifuge tube. The final volume was made up to 20 μl by adding sterile distilled water and was mixed well. These tubes were incubated at room temperature for 10 min and then were incubated at 42 °C for one hr. The M-MuLV enzyme inactivation step was done by a step for 10 min at 70 °C. The synthesized cDNA was diluted 10 times in sterile distilled water and was used as a template for quantitative real-time PCR analysis.

Quantitative real-time PCR {#sec2-6}
--------------------------

Expression of E-cadherin mRNA was analyzed by quantitative real-time PCR using the SYBR Premix Ex Taq II kit (TAKARA Bio INC., Otsu, Japan) on an Applied Biosystems^®^ StepOnePlus™ Real-Time PCR system (Applied Biosystems, Foster city, CA, USA). Quantitative real-time PCR was performed using the following primer sequences: E-cadherin, forward: 5'-AGGGGTTAAGCACAACAGCA-3' and reverse: 5'-GG-TATTGGGGGCATCAGCAT-3'; HPV E7, forward: 5'-ATGCATGGAG ATACACCTAC-3' and reverse: 5'-TTATGGTTTCTGAGAACAGATG-3', and glyceral-dehyde 3-phosphate dehydrogenase (GAPDH), forward: 5'-ATGTTCGTCATGGGTGTGAA-3' and reverse: 5'-GGTGCTAAGCAGTTGGTGGT-3'. Briefly, 10 μl SYBR Premix Ex Taq II (2x), 0.4 μl ROX Reference Dye (50x), and 0.8 μl of forward and reverse primers with 2 μl of 1/10 diluted cDNA were used in a total volume of 20 μl. The temperature profile for all genes was 95 °C for 1 min; 40 cycles of 95 °C for 15 sec, 55 °C for 30 sec, and 72 °C for 30 sec; melting curve program (60-95 °C). All samples were run in triplicate simultaneously with negative controls. The threshold cycle (ct) of E-cadherin mRNA level of VPA treated cell lines was compared with the threshold cycle generated by the control samples. E-cadherin mRNA levels were normalized to the expression of the endogenous housekeeping gene GAPDH by the 2^--ΔΔct^ method ([@ref29]).

Statistical analysis {#sec2-7}
--------------------

The unpaired, two-tailed student's *t* was done to analyze the statistical differences between groups using Graph-Pad Prism software. mRNA levels comparisons between groups were analyzed using ANOVA test. A *P*-value less than 0.05 (*P*\<0.05) was considered to be statistically significant for the differences and determined by asterisk in the corresponding figures.

Results {#sec1-3}
=======

Optimization of the valproic acid concentration for E-cadherin expression {#sec2-8}
-------------------------------------------------------------------------

The cell lines were treated by 1, 2, and 5 mM VPA and harvested 24, 48, and 72 hr after treatment. MMT assay and quantitative real-time PCR results for E-cadherin mRNA levels showed that 2 mM VPA after 48 hr gave the highest amount of E-cadherin expression (data not shown).

Valproic acid up-regulated E-cadherin expression in HPV negative cell lines {#sec2-9}
---------------------------------------------------------------------------

Two HPV positive cell lines, HCT~116~ and MKN~45~, were treated by 2 mM VPA to study the E-cadherin mRNA level changes. Cells were harvested 48 hr after treatment, total RNA was extracted, and cDNA was synthesized by 1 μg RNA. Then E-cadherin expression was analyzed by quantitative real-time PCR. Each experiment was done three times (n=3). The results revealed that E-cadherin expression is increased 1.7 and 2 times in HCT~116~ and MKN~45~ cell lines in comparison to control cells with *P*-value= 0.0423 and *P*-value = 0.0042, respectively (Figure [1A](#F1){ref-type="fig"}, [B](#F1){ref-type="fig"}).

![**E-cadherin expression is increased in human papillomavirus negative cell lines by valproic acid**. HCT~116~ and MKN~45~ cell lines were treated by 2 mM VPA when the cells reached 80% confluency. After 48 hr of treatment, cells were harvested and fold change of E-cadherin expression was analyzed by real time PCR using the 2^--ΔΔCt^ method. (**A**) E-cadherin mRNA level in HCT~116~ cells treated by VPA. (**B**) E-cadherin mRNA level in MKN~45~ cells treated by VPA. Each experiment was done three times (n=3). \* *P*\< 0.05, \*\* *P*\< 0.01](IJBMS-19-601-g001){#F1}

E-cadherin expression is increased in HPV positive cell lines by valproic acid {#sec2-10}
------------------------------------------------------------------------------

The two HPV positive cell lines, HeLa and TC~1~ were treated by 2 mM VPA, and E-cadherin mRNA level was analyzed. Each experiment was done three times (n=3). The results showed that E-cadherin mRNA level is significantly up-regulated, 3.2 and 2.6 times in HeLa and TC~1~ cell lines with *P*-value = 0.0028 and *P*-value = 0.0089, respectively (Figure [2A](#F2){ref-type="fig"}, [B](#F2){ref-type="fig"}).

![**Valproic acid up-regulated E-cadherin expression in human papillomavirus positive cell lines**. Hela and TC~1~ cell lines were cultured by DMEM containing 2 mM VPA. After 48 hr treatment, cells were harvested and fold change of E-cadherin expression was analyzed by real time PCR using the 2^--ΔΔCt^ method. (**A**) E-cadherin mRNA level in Hela cell line treated by VPA. (**B**) E-cadherin mRNA level in TC~1~ cell line treated by VPA. Each experiment was done three times (n=3). \* *P*\< 0.05, \*\* *P*\< 0.01](IJBMS-19-601-g002){#F2}

The E-cadherin augmentation is induced by valproic acid in HPV positive cell lines higher than HPV negative cell lines are {#sec2-11}
--------------------------------------------------------------------------------------------------------------------------

The experiments showed that E-cadherin expression is increased by VPA in both in HPV positive and negative cell lines; whereas, E-cadherin augmentation in HeLa and TC~1~ (Mean=2.9), HPV positive cell lines, is higher than HPV negative cell lines, MKN~45~ and HCT~116~ (Mean=1.85) ([Figure 3](#F3){ref-type="fig"}).

![The E-cadherin augmentation induced by valproic acid in HPV positive cell lines is higher than HPV negative cell lines](IJBMS-19-601-g003){#F3}

Valproic acid down-regulated HPV E7 expression in HeLa and TC~1~ cell lines {#sec2-12}
---------------------------------------------------------------------------

Previous studies revealed the relationship between HPV E7 oncoprotein and E-cadherin expression. One study showed that expression of the HPV~16~ E7 reduces the expression of E-cadherin in MDCK cells, and Caberg *et al* demonstrated that suppression of HPV E7 using siRNA in HPV~16~ transformed human keratinocytes, restores the E-cadherin expression in these cells ([@ref30], [@ref31]). So, we set out to test the VPA effects on HPV E7 expression in HeLa and TC~1~ cell lines. Each experiment was done three times (n=3). The results showed that HPV E7 expression is decreased 5.2 and 4 times in HeLa and TC~1~ cell lines with *P*-value= 0.0058 and *P*-value= 0.0069, respectively (Figure [4A](#F4){ref-type="fig"}, [B](#F4){ref-type="fig"}).

![**Valproic acid down-regulated HPV E7 expression in human papillomavirus positive cell lines**. Hela and TC~1~ cell lines were treated by 2 mM VPA. After 48 hr of treatment, cells were harvested and fold change of HPV E7 expression was analyzed by real time PCR using the 2^--ΔΔCt^ method. (**A**) HPV E7 expression in Hela cell line treated by VPA. (**B**) HPV E7 expression level in TC~1~ cell line treated by VPA. Each experiment was done three times (n=3). Error bars represent SEM. \* *P*\< 0.05, \*\* *P*\< 0.01](IJBMS-19-601-g004){#F4}

Discussion {#sec1-4}
==========

Epigenetic is composed inducible genetic changes that regulates gene expression. DNA methylation and histone acetylation are two most common mechanisms that induce epigenetic changes ([@ref32]). DNA methylation occurs at cytosine within CpG islands and it is catalyzed by DNA methyltransferases (DNMTs) protein family ([@ref33]). DNA methylation directly interferes with transcription factors binding to recognition regions in promoter sites, and causes transcriptional suppression ([@ref34]). Interaction of DNMTs with other chromatin modifying enzymes such as HDACs and histone methyltransferase brings these proteins in the vicinity of promoter sites and alters gene expression ([@ref35]-[@ref38]).

Positive charge at lysine residues neutralized by histone acetylation, loosen the chromatin structure that finally causes transcriptionally active chromatin ([@ref9], [@ref10]). DNMTs bring HDACs in the vicinity of promoter regions, cause local histone deacetylation, and condense chromatin structure that reduce gene expression levels by limiting accessibility of transcription factors to this sites ([@ref39]). HDACs include 18 genes that are divided into 4 classes ([@ref13]).

HDACIs have emerged as the hopeful clinical drugs for cancer ([@ref11], [@ref12]). VPA has proven as one of the most encouraging useful therapeutics with anticancer properties. In comparison with other HDACIs such as trapoxin and trichostatin A that have toxic side effects, VPA is relatively nontoxic and safe *in vivo* ([@ref13]). VPA inhibits invasion and migration of tumor cells by several mechanisms ([@ref16]-[@ref19]).

During epithelial to mesenchymal transition (EMT) process, a malignant cell can break away from the cancerous tumor ([@ref40]). A critical molecular feature of EMT is the downregulation of E-cadherin ([@ref41]). E-cadherin acts as a tumor suppressor protein and inhibits invasion and metastasis. ([@ref42]).

EMT provides molecular mechanisms for cervical cancer metastasis, and decreased or aberrant expression of E-cadherin have been reported in cervical carcinoma ([@ref43]-[@ref45]).

Carcinoma of the cervix is the second most common cancer in women worldwide ([@ref1]). Development of this cancer is caused by the integration of hrHPVs in the host genome (4 HPV E6 and E7 viral proteins may induce EMT in cervical cancer ([@ref46], [@ref47]), so in this study we analyzed valproic acid effects on E-cadherin expression in HPV positive cell lines and HPV negative cell lines.

Our results showed that E-cadherin expression is increased in HPV positive cell lines (HeLa and TC~1~) and HPV negative cell lines (MKN~45~ and HCT~116~); this result is consistent with previous studies. The expression of E-cadherin is up-regulated by VPA in LNCaP, DU~145~, PC~3~, and luminescent PC~3~ prostate cancer cell lines and prostate cancer xenograft mouse models ([@ref48]). The VPA effects on ovarian cancer using human ovarian cancer cell line SKOV~3~ and a human ovarian cancer model transplanted subcutaneously in nude mice showed increased expression of E-cadherin and reduced matrix metalloproteinase-9 and VEGF *in vitro* and *in vivo* ([@ref49]). VPA and SAHA treatment, in combination with all-trans retinoic acid (ATRA), restore E-cadherin, TSGs RARb~2~, P~53~, and P~21~CIP~1~ expression in human cervical cancer cells ([@ref50]). It has been also reported that S-valproate reduces transcriptional suppressor of E-cadherin proteins vimentin and ZEB~1~ and increases E-cadherin protein expression in non-small cell lung cancer ([@ref51]). Based on previous studies, VPA treatment increases the expression of E-cadherin in RM~1~ and PC~3~ cell lines, and might be useful to inhibit E-cadherin-mediated migration in prostate cancer cells ([@ref52], [@ref53]).

The effects of VPA on cervical cancer cell lines have been also investigated before. VPA has shown a growth inhibitory effect on HeLa, SiHa, and CaSki cervical cancer cell lines ([@ref54], [@ref55]). VPA increases p53 transcription and protects it from degradation by E6 ([@ref54]). Evaluating the effects of VPA on cervical cancer cell lines HeLa, SiHa, and CaSki and *in vivo* cancer models demonstrated increased p21 expression and histone H~3~ acetylation. Chronic treatment of VPA significantly decreased tumor growth and improved survival in tumor xenograft studies ([@ref56]). Another study revealed that VPA treatment suppresses cell growth and induces cell cycle arrest in human cervical cancer HeLa cells, and also increases the tumor suppressor, Notch~1~ ([@ref57]).

According to our findings, E-cadherin augmentation in HPV positive cell lines, HeLa and TC-1, is higher than HPV negative cell lines, MKN~45~ and HCT~116~. Previous studies have showed the effect of HPV E7 oncoprotein on E-cadherin expression, one study revealed that the expression of the HPV~16~ E7 in MDCK cells reduces the expression of E-cadherin ([@ref30]), and suppression of HPV E7 using siRNA in HPV~16~ transformed human keratinocytes restores the E-cadherin expression in this cell ([@ref31]). We studied the effects of VPA on HPV E7 expression in HeLa and TC~1~ cell lines; VPA significantly decreased HPV E7 mRNA level in both cell lines. This reduction of HPV E7 expression by VPA might lead to more augmentation of E-cadherin in HPV positive cell lines.

Conclusion {#sec1-5}
==========

VPA increases E-cadherin expression in HPV positive cell lines and HPV negative cell lines; however, E-cadherin augmentation in HPV positive cell lines is higher than HPV negative cell lines. VPA decreases HPV E7 mRNA level in HeLa and TC-1 cell lines, which might lead to augmentation of E-cadherin in HPV positive cell lines. VPA showed anticancer properties and could potentially be a promising candidate for further cervical cancer treatment.
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